Cumulative one-year incidence of follow-up albuminuria testing was 6.7 percent among participants with abnormal protein dipstick result<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Sept. 30, 2024 (HealthDay News) — Few patients with abnormal protein dipstick results have follow-up albuminuria quantification, according to a research letter published online Oct. 1 in the Annals of Internal Medicine<\/em>.<\/p>\n Noting that guidelines recommend follow-up albumin-creatinine ratio (ACR) testing if the protein dipstick test result is abnormal, Yunwen Xu, Ph.D., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues examined follow-up albuminuria quantification after an initial abnormal result on a protein dipstick test.<\/p>\n Overall, 13 percent of the 1,042,740 participants with urine dipstick testing in 33 U.S. health systems had an abnormal protein dipstick test result. The researchers found that the cumulative one-year incidence of follow-up albuminuria testing was 6.7 and 4.0 percent among participants with abnormal dipstick test results at baseline and those with normal results at baseline, respectively. Slightly higher follow-up testing rates were seen with higher values of the initial abnormal test: 6.3, 7.3, and 8.0 percent for 1+, 2+, and 3+ or greater protein, respectively. Follow-up testing occurred more often in those with versus without diabetes (16.6 versus 3.8 percent). Among the 7,967 participants with initial abnormal results on a dipstick protein test with follow-up albuminuria quantification testing, 43.3 percent had a positive result confirming albuminuria. There was an increase in this percentage with higher baseline protein levels from 36.3 to 53.0 to 64.9 percent for 1+, 2+, and 3+ or greater protein.<\/p>\n “Improved education on the necessity of follow-up albuminuria quantification and the implementation of guideline-recommended ACR testing would benefit many patients through earlier detection and treatment of albuminuric chronic kidney disease,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n